Clinuvel scores long-awaited FDA win for rare skin disease implant Scenesse

9th October 2019 Uncategorised 0

It wasn’t so long ago that Australian drugmaker Clinuvel spurned a buyout attempt by Retrophin and its wayward then-CEO Martin Shkreli, preferring to soldier on alone with its sole drug candidate. Now, that drug has scored its FDA approval, and Clinuvel’s poised for a big leap in value.

More: Clinuvel scores long-awaited FDA win for rare skin disease implant Scenesse
Source: fierce